Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that careful diagnosis is crucial for chromosome 13q deletion syndrome, tamoxifen can cause reversible eye damage, finasteride may be linked to cataracts, and OCT is useful for diagnosing macular diseases.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Radiotherapy is a good option when further surgery for skin cancer isn't preferred, but more research is needed to compare it with other methods.

Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.

Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.

Topical calcitriol is safe for preventing hair loss during chemotherapy.

Topical calcitriol appears safe and may reduce hair loss during chemotherapy.

The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

Scalp cooling therapy helps preserve hair during chemotherapy for most patients.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

Older ovarian cancer patients live longer and tolerate weekly chemotherapy better than three-weekly treatments.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

MK-5108 is safe and shows potential against tumors, especially alone.

Treatment with 5α-reductase inhibitors is linked to a delay in prostate cancer diagnosis and may affect survival rates.

Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.

A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.

5ARIs like finasteride can help prevent prostate cancer and treat BPH, but guidelines should be updated to reflect this.

GT20029 showed some hair growth improvement, but longer studies are needed for better results.

Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.